ReviewTrends in biotechnology2011
Genome-wide approaches for cancer gene discovery.
Review in Trends in biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma.Molecular therapy oncolytics · 2019Article
- Transcriptional Analysis-Based Integrative Genomics Approach to Identify Tumor-Promoting Metabolic Genes.Methods in molecular biology (Clifton, N.J.) · 2017Article
- The epigenetic landscape of Alu repeats delineates the structural and functional genomic architecture of colon cancer cells.Genome research · 2017Article
- Large-Scale RNA Interference Screening to Identify Transcriptional Regulators of a Tumor Suppressor Gene.Methods in molecular biology (Clifton, N.J.) · 2017Article
- Identification of novel direct targets of Drosophila Sine oculis and Eyes absent by integration of genome-wide data sets.Developmental biology · 2016Article
- Alternative splicing within the Wnt signaling pathway: role in cancer development.Cellular oncology (Dordrecht, Netherlands) · 2016Review
- Multiple signatures of a disease in potential biomarker space: Getting the signatures consensus and identification of novel biomarkers.BMC genomics · 2015Article
- Identification and characterization of human MIBP1 gene in glioma cell differentiation.Journal of molecular neuroscience : MN · 2014Article
- Clinical, molecular- and cytogenetic analysis of a case of severe radio-sensitivity.Current genomics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
One of the central aims of cancer research is to identify and characterize cancer-causing alterations in cancer genomes. In recent years, unprecedented advances in genome-wide sequencing, functional genomics technologies for RNA interference screens and methods for evaluating three-dimensional chromatin organization in vivo have resulted in important discoveries regarding human cancer. The cancer-causing genes identified from these new genome-wide technologies have also provided opportunities for effective and personalized cancer therapy. In this review, we describe some of the most recent technologies for cancer gene discovery. We also provide specific examples in which these technologies have proven remarkably successful in uncovering important cancer-causing alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.